It appeared that almost all of the examined compounds (besides 5-HT1A receptor agonist 8-OH-DPAT, SSRI fluvoxamine against SH-SY5Y and AB9 against both tumor lines) exhibited moderate to high cytotoxic activity at the micromolar level against neuroblastoma and prostate cancer cells (Table 2). This evidence concerns the gene HTR1A and Familial prostate cancer.